Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Other Accumulated Expenses (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed Other Accumulated Expenses for 15 consecutive years, with $219000.0 as the latest value for Q2 2025.

  • On a quarterly basis, Other Accumulated Expenses changed N/A to $219000.0 in Q2 2025 year-over-year; TTM through Jun 2025 was $219000.0, a N/A change, with the full-year FY2024 number at $227000.0, down 83.42% from a year prior.
  • Other Accumulated Expenses was $219000.0 for Q2 2025 at Gyre Therapeutics, down from $227000.0 in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $8.1 million in Q3 2021 to a low of $118000.0 in Q4 2022.
  • A 5-year average of $2.7 million and a median of $1.2 million in 2022 define the central range for Other Accumulated Expenses.
  • Peak YoY movement for Other Accumulated Expenses: plummeted 97.77% in 2022, then skyrocketed 1060.17% in 2023.
  • Gyre Therapeutics' Other Accumulated Expenses stood at $4.1 million in 2021, then plummeted by 97.1% to $118000.0 in 2022, then surged by 1060.17% to $1.4 million in 2023, then tumbled by 83.42% to $227000.0 in 2024, then fell by 3.52% to $219000.0 in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Other Accumulated Expenses are $219000.0 (Q2 2025), $227000.0 (Q4 2024), and $1.4 million (Q4 2023).